PARK2 Antilichaam

Parkinson's disease (PD) is a neurodegenerative disease whose symptoms include tremors, rigidity, bradykinesia, and postural instability (1) . Mutations in the PARK2 gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease (2) . The PARK2 protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation (3) . Recent studies have suggested that PARK2 expression reduces the mitochondrial accumulation of the apoptosis protein Bax under basal conditions and directly ubiquitinates Bax, thereby promoting cell survival (4) .

5071

O60260

NP_004553

Human

Unconjugated

Primary Antibodies

Neuroscience, Apoptosis

PARK2 antibody is affinity chromatography purified via peptide column.

Cat. No. 1362 - Human Cerebellum Tissue Lysate

1 mg/mL

PARK2 antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

PARK2 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

IgG

PARK2 antibody is human specific.

PARK2

Cat. No. 10-301 - Human Brain Tissue Slide

Parkin RBR E3 ubiquitin protein ligase

Homo sapiens

Dauer W and Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003; 39:889-909.

Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-8.

Shimura H, Hattori N, Kubo Si, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000; 25:302-5.

Johnson BN, Berger AK, Cortese GP, et al. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc. Natl. Acad. Sci. USA 2012; 109:6283-88.

PARK2 Antibody: PDJ, PRKN, AR-JP, LPRS2, E3 ubiquitin-protein ligase parkin, Parkinson juvenile disease protein 2, Parkinson disease protein 2

ELISA, WB, IHC-P, IF

169790969

Liquid